FLT3 EXPRESSING HEMATOLOGICAL MALIGNANCIES

Clinical trials for FLT3 EXPRESSING HEMATOLOGICAL MALIGNANCIES explained in plain language.

Never miss a new study

Get alerted when new FLT3 EXPRESSING HEMATOLOGICAL MALIGNANCIES trials appear

Sign up with your email to follow new studies for FLT3 EXPRESSING HEMATOLOGICAL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Scientists test 'Off-the-Shelf' cell therapy for tough blood cancers

Disease control Ongoing

This is a first-in-human study to find a safe dose of a new, ready-made cell therapy called SENTI-202. It is for adults with advanced blood cancers, like AML or MDS, that have come back or stopped responding to standard treatments. The main goals are to check the safety of the tr…

Matched conditions: FLT3 EXPRESSING HEMATOLOGICAL MALIGNANCIES

Phase: PHASE1 • Sponsor: Senti Biosciences • Aim: Disease control

Last updated Mar 30, 2026 14:28 UTC

FLT3 EXPRESSING HEMATOLOGICAL MALIGNANCIES

Get alerted when new FLT3 EXPRESSING HEMATOLOGICAL MALIGNANCIES trials appear

Scientists test 'Off-the-Shelf' cell therapy for tough blood cancers